Fluxion Biosciences, Stanford collaborate on circulating tumor cell analysis

Friday, June 29, 2012 11:45 AM

Fluxion Biosciences, a San Francisco-based provider of cellular analysis tools for use in critical life science, has formed a collaboration with the Stanford University School of Medicine to develop tests to help deliver more effective therapies to cancer patients.

The collaboration will focus on breast and lung cancer pathologies. The research is designed to help subtype different forms of the disease and develop more effective treatments tailored to each patient.

Dr. Stefanie Jeffrey’s laboratory at Stanford will be utilizing Fluxion’s IsoFlux System to isolate, recover and analyze rare circulating cancer cells at the molecular level. The IsoFlux System utilizes a proprietary microfluidic technology to isolate rare cells with high efficiency. Samples coming from the IsoFlux System are immediately ready for downstream analysis. A variety of analytical techniques are available for isolated cell samples such as mutation detection, gene expression, sequencing, and protein analysis.

“We are very excited to be working with Dr. Jeffrey on this project,” said Michael Schwartz, program director at Fluxion. “She is widely respected as a leader in the field of personalized cancer therapies, and is backed by the support of a world-class medical institution at Stanford.”

Share:          
CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs